Carna Biosciences, Inc. announced that it has received ¥13.41925 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm

Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.